The concomitant utilization of OXYCONTIN and CYP3A4 inducers can lessen the plasma focus of oxycodone [see CLINICAL PHARMACOLOGY], causing diminished efficacy or onset of a withdrawal syndrome in patients who have designed Actual physical dependence to oxycodone [see WARNINGS AND PRECAUTIONS].The maker of OxyContin painkillers has arrived at an $8.